Consider his recent remarks at the IOM symposium on the drug safety challenges faced by the FDA. Mark makes a very strong case that the agency should make more use of the pooled information contained in large health-care databases, like those run by private insurers that include information about 100 million Americans.
According to McClellan, surveillance, for problems like the increased risk of heart attack and stroke that led to the withdrawal of the popular painkiller Vioxx in 2004, could broaden the FDAâ€™s view of drug safety problems as they emerge while respecting patient confidentiality.
Here's a link to the media report on Mark's comments:
That's FDA reform for all -- not just REMS for Dems.